Global HCP Transparency Study
Regulatory disclosure challenges and program guidance for life sciences companies
Deloitte has executed a Global Health Care Professional(HCP) Transparency Study to provide insights into countries’ current and anticipated regulatory requirements for tracking payments and transfers of value that life sciences companies make to health care professionals and organizations (HCP/O).
While U.S. pharmaceutical manufacturers have been dealing with the federal Sunshine Act and state-level transparency laws for some time, new and pending legislation such as France’s disclosure law, Loi relative au renforcement de la sécurité sanitaire du médicament et des produits de santé, which was passed in December 2011 and the European Federation of Pharmaceutical Industries and Associations’ (EFPHA) draft Code on Disclosure of Transfers of Value from Pharmaceutical Companies to HCP and HCO, which is scheduled to go into effect in 2014, are the latest in a series of transparency related legislation and industry codes being instituted around the globe (Figure 1 in attached PDF). In fact, we estimate that over 70 percent of pharmaceutical sales will occur in countries which have HCP Transparency regulations in place by 2015. (Figure 2 in attached PDF)
This report summarizes our findings and provides guidance for life sciences companies on how to address global HCP transparency challenges.
Download the above PDF to learn more.
As used in this document, “Deloitte” means Deloitte Consulting LLP a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.